January 29, 2019

Verseon Corporation (“Verseon” or the “Company”)

Directorate change

Fremont, Calif.—Verseon Corporation (AIM:VSN), a technology-based pharmaceutical company, announces that Xavier Rolet, on account of his recent executive appointment, will be stepping down from his role as a non-executive director on February 23, 2019 in order to avoid any potential conflicts with Verseon and its subsidiaries’ businesses.

“We thank Xavier for his contribution and wish him every success in his new role,” said Adityo Prakash, CEO of Verseon.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform paired with a comprehensive in-house chemistry and biology workflow to build a growing drug development pipeline. Through its wholly owned subsidiary BlockRules Ltd., Verseon is also pioneering blockchain technology for regulated securities.


For further information please contact:

Verseon Corporation www.verseon.com
Sebastian Wykeham / Tina Schlafly +1 (510) 225 9000
Arden Partners (NOMAD and Joint Broker)  
Ruari McGirr / Ciaran Walsh +44 (0) 20 7614 5900
Cantor Fitzgerald Europe (Joint Broker)  
Phil Davies +44 (0) 20 7894 7000

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisors)
Henry Harrison-Topham / Jamie Hooper +44 (0) 20 7466 5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890

Our pledge

Verseon is committed to growth through innovation, building value for its shareholders while respecting its responsibilities as a good corporate citizen